BioLine RX (Israel) Performance
| BLRX Stock | ILS 1.50 0.10 6.25% |
The firm shows a Beta (market volatility) of 0.3, which signifies not very significant fluctuations relative to the market. As returns on the market increase, BioLine RX's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioLine RX is expected to be smaller as well. At this point, BioLine RX has a negative expected return of -0.42%. Please make sure to confirm BioLine RX's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if BioLine RX performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days BioLine RX has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 16.8 M | |
| Total Cashflows From Investing Activities | -38.2 M |
BioLine |
BioLine RX Relative Risk vs. Return Landscape
If you would invest 200.00 in BioLine RX on November 3, 2025 and sell it today you would lose (50.00) from holding BioLine RX or give up 25.0% of portfolio value over 90 days. BioLine RX is generating negative expected returns and assumes 4.5497% volatility on return distribution over the 90 days horizon. Simply put, 40% of stocks are less volatile than BioLine, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BioLine RX Target Price Odds to finish over Current Price
The tendency of BioLine Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.50 | 90 days | 1.50 | about 89.84 |
Based on a normal probability distribution, the odds of BioLine RX to move above the current price in 90 days from now is about 89.84 (This BioLine RX probability density function shows the probability of BioLine Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon BioLine RX has a beta of 0.3 suggesting as returns on the market go up, BioLine RX average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding BioLine RX will be expected to be much smaller as well. Additionally BioLine RX has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. BioLine RX Price Density |
| Price |
Predictive Modules for BioLine RX
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioLine RX. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioLine RX Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioLine RX is not an exception. The market had few large corrections towards the BioLine RX's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioLine RX, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioLine RX within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.57 | |
β | Beta against Dow Jones | 0.30 | |
σ | Overall volatility | 0.22 | |
Ir | Information ratio | -0.13 |
BioLine RX Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioLine RX for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioLine RX can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioLine RX generated a negative expected return over the last 90 days | |
| BioLine RX may become a speculative penny stock | |
| BioLine RX has high historical volatility and very poor performance | |
| Net Loss for the year was (27.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLine RX has accumulated about 40.61 M in cash with (23.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. |
BioLine RX Fundamentals Growth
BioLine Stock prices reflect investors' perceptions of the future prospects and financial health of BioLine RX, and BioLine RX fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioLine Stock performance.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | (13.02 M) | |||
| Shares Outstanding | 922.87 M | |||
| Price To Book | 0.77 X | |||
| EBITDA | (25.37 M) | |||
| Cash And Equivalents | 40.61 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 10.69 M | |||
| Debt To Equity | 23.20 % | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (23.57 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 81.39 M | |||
| Retained Earnings | (163 M) | |||
| Current Asset | 46 M | |||
| Current Liabilities | 3 M | |||
About BioLine RX Performance
By analyzing BioLine RX's fundamental ratios, stakeholders can gain valuable insights into BioLine RX's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioLine RX has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioLine RX has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. BioLineRx Ltd. was founded in 2003 and is based in Modiin, Israel. BIOLINE RX operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 48 people.Things to note about BioLine RX performance evaluation
Checking the ongoing alerts about BioLine RX for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioLine RX help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioLine RX generated a negative expected return over the last 90 days | |
| BioLine RX may become a speculative penny stock | |
| BioLine RX has high historical volatility and very poor performance | |
| Net Loss for the year was (27.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLine RX has accumulated about 40.61 M in cash with (23.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. |
- Analyzing BioLine RX's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioLine RX's stock is overvalued or undervalued compared to its peers.
- Examining BioLine RX's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioLine RX's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioLine RX's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioLine RX's stock. These opinions can provide insight into BioLine RX's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioLine Stock analysis
When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |